Merging Natural Products: Muraymycin–Sansanmycin Hybrid Structures as Novel Scaffolds for Potential Antibacterial Agents
作者:Giuliana Niro、Stefanie C. Weck、Christian Ducho
DOI:10.1002/chem.202003387
日期:2020.12.15
different Gram‐positive and Gram‐negative bacteria, which are poorly understood so far. Herein, the synthesis of a novel hybrid structure is reported, derived from the 5′‐defunctionalized uridine core moiety of muraymycins and the peptide chain of sansanmycin B, as a new scaffold for the development of antimicrobial agents. The reported muraymycin–sansanmycin hybrid scaffold showed nanomolar activity against
为了克服细菌耐药性,迫切需要新型抗菌剂。所谓的核苷抗生素类别为开发新抗生素提供了有希望的候选者,因为这些化合物阻断了临床上未开发的细菌靶点:整合膜蛋白MraY,细胞壁(肽聚糖)生物合成中的关键酶。除了尿苷衍生的核心基序外,核苷抗生素还表现出显着的结构多样性。一些亚类还对不同的革兰氏阳性和革兰氏阴性细菌表现出特定的选择性,但迄今为止人们对此知之甚少。在此,报道了一种新型混合结构的合成,该结构源自穆雷霉素的 5'-去功能化尿苷核心部分和桑桑霉素 B 的肽链,作为开发抗菌药物的新支架。报道的穆雷霉素-山散霉素混合支架对细菌靶酶MraY表现出纳摩尔级活性,但对金黄色葡萄球菌、大肠杆菌和铜绿假单胞菌没有显着的抗菌活性。